InsiderClue
Stocks · Health care · Biological Products, (No Diagnostic Substances)

Maze Therapeutics, Inc.

MAZE Clue Score57
United States Fiscal year ends December CIK 0001842295
$27.11 +4.75% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $27.11 −5.74% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 31 Jan 2025. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back. P/E and P/FCF are the market value over the last full fiscal year's net income or free cash flow, as public on each day, so they step once a year when the annual report comes out. A hatched band marks a stretch with none: a year of net loss, or of cash burnt.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
RevenueOperating incomeNet income
Fiscal year 2024Revenue167.5Operating income57.6Net income52.2EPS, diluted1.25Fiscal year 2025Operating income−142.9Net income−131.1 −351.0%EPS, diluted−3.05
FY2024FY2025
Revenue 167.5 n/a
Growth
Operating income 57.6 −142.9
Net income 52.2 −131.1
Growth −351.0%
EPS, diluted 1.25 −3.05

Margins

How much of each dollar of revenue it keeps. Point at a year for the detail.
Operating marginNet margin
Fiscal year 2024Operating margin34.4%Net margin31.2%Free cash flow margin44.7%Fiscal year 2025
FY2024FY2025
Operating margin 34.4% n/a
Net margin 31.2% n/a
Free cash flow margin 44.7% n/a

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2024Operating cash flow76.0Capital expenditure−1.1Free cash flow74.8Fiscal year 2025Operating cash flow−111.9Capital expenditure−0.8Free cash flow−112.7 −250.7%
FY2024FY2025
Operating cash flow 76.0 −111.9
Capital expenditure −1.1 −0.8
Free cash flow 74.8 −112.7
Growth −250.7%

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash
Fiscal year 2024Cash196.8Shareholders’ equity−311.2Fiscal year 2025Cash189.2Shareholders’ equity355.0
FY2024FY2025
Cash 196.8 189.2
Shareholders’ equity −311.2 355.0

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Income statement

In millions of USD, except per-share figures; shares in millions. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2024 31 Dec 2024 FY2025† 31 Dec 2025
Revenue and profit
167.5 n/a
Growth
83.5 108.4
26.4 34.5
57.6 −142.9
Growth −348.1%
53.4 −131.1
1.2 0.0
52.2 −131.1
Growth −351.0%
Per share
1.42 −3.05
1.25 −3.05
Growth −344.0%
2.4 43.0
2.7 43.0
Growth +1,474.0%

† The diluted share count jumps at 2025, so per-share figures either side of that column are not comparable. Usually a split, but the break lands on the restatement boundary rather than on the split date, because every column is that period’s latest filing.

Five years in brief

Worked out from the figures above, not from a press release
  • A net loss in 1 of 2 years on file.